CELL & GENE THERAPY PRODUCTS 2024

MANUFACTURING, QUALITY AND REGULATORY CONSIDERATIONS

KNOWLEDGE SHARING AND **CAPACITY BUILDING**

- There is a need for speed, but we *cannot compromise quality*.
- Potency assurance strategy is *more than potency testing*.
- To ensure safe and efficacious administration of gene edited products to patients, *minimizing unintended effects is paramount*.
- There is an *evolution of product understanding*, particularly in the application of analytical methods used to support process development and characterize or monitor product attributes.
- ICH provides a harmonized approach to ensure that *safe, effective and high-quality medicines are developed, registered, and maintained* in a resource efficient manner whilst meeting high standards.

Cell & Gene Therapy Products 2024 **BY THE NUMBERS**

First-Time Attendees

126

Regulators Participated

51

Company Participation

129

Country Participation

18

Austria | Belgium | Canada | China | Denmark | Finland | France | Germany | Ireland | Italy | Japan | Netherlands | Portugal | Saudi Arabia | Spain | Sweden | United Kingdom | United States

CASSS™

SHARING SCIENCE **SOLUTIONS**